Minister, I know that you share with me concerns that, every day that passes, we have patients in Wales who aren't able to access these extremely important drugs. Now, on 25 October, you said that you and your officials were meeting with representatives from Vertex the following week to discuss details of these terms and how they might be applied. I do understand you've got company confidentiality issues here, but are you able to give us any form of update on that? 

May I also ask what lessons have been learned from the length of time that it's taken to make progress on this issue, and how could things be done differently in future to ensure that we're not left behind the curve when it comes to reaching agreements on making life-saving drugs available for Welsh patients?

And finally, in terms of learning lessons, I understand that in early 2018, the company had been in discussions with NHS Wales on a portfolio proposal for all their current and future cystic fibrosis medicines. However, and I'm directly quoting, these discussions were halted in March/April, due to what we understood at the time to be a staffing issue at NHS Wales all-Wales medicines procurement. Minister, can you shed any light on that and provide assurances that such hold-ups will not happen again?